Do you already not discovered new medicines?

31 05 2012

A few decades ago the industry pharmaceutical developed countless tablets to reduce blood pressure, controlling glucose and cholesterol in the blood and prevent infections.


Today, very few medicines seem to go to market.

And it is that produce and take a new drug to the clinic might cost $1 billion and is a process which can take more than 15 years.

The industry is facing multiple crises, budgets increasingly reduced and huge scientific challenges.

Is this the end of the new pharmaceutical discoveries?

Margaret Chan, Director of the World Health Organization, He recently warned that the world is leading to a “was post-antibioticos” and that you will come the moment that many of the most common infections already not may be cured.

This is due to the growing resistance to antibiotics currently available.

And as the population ages, scientists struggle to find forms — and drugs- to combat the growing epidemic of nerve diseases such as Alzheimer's and Parkinson's.

Apparently, the old model of drug development is already not working.

This method, in which industry committed huge amounts of money to try to find a drug that could treat to enormous proportions of the population - and generate “mountains” cash to cover other losses- You can no longer sustain the industry.


Huge vacuum

The model is inefficient. In nine of each 10 sometimes, molecules that show promise in the early stages fail in more advanced trials.

Another great pressure for pharmaceutical is when the patents on some of their most lucrative drugs expire.

And is becoming more difficult for scientists to find the white suitable for a chemical compound.

As explained by Professor Chas Bountra, expert in translational medicine at the University of Oxford, “We have failed to understand enough about human diseases or enough above how Act existing compounds”.

“If we don't understand that, We can not design molecules superior and better”.

Another problem, Adds, It is the process of duplication in the development of a drug.

“We tend not to publish our failures, or if we publish them, do it too late”, expresses the Professor Bountra.

“As a result, other academics and other companies that are working on the same goal, continue wasting resources and careers and exposing patients to molecules that have the possibility of failure”.

El proceso para producir un nuevo fármaco puede demorar hasta 15 años.

The process to produce a new drug may take up to 15 years.

Open industry

Professor Patrick Vallance, President of pharmaceutical research and development by GlaxoSmithKline (GSK) He believes that the industry is every more open.

“One of the things we have done is to be very open about compounds that they go to the clinic”.

“We publish our results and make available our protocols for scientific review when we deliver our studies”.

“Such things help to a better visibility of what is being” Adds.

But at the same time, argues, “We have to be realistic”.

“There will always be some degree of duplication because this is part of the competition”.

For its part, Professor Paul Workman of the Institute of Cancer Research says that there is another important issue.

“With the problems of the financial crisis has developed a kind of vacuum that many describe as 'Valley of death'” says.

“It is the Valley between basic research and innovation, on the one hand, and the benefit of the patients and commercial success, on the other hand”.

“With a huge division in the middle which shows a lack of investment and many failures”.



A possible solution, experts believe, is that charitable foundations, as the Wellcome Trust, investment offered to fill the division.

The Workman Professor believes that the most successful model is the one where many processes for the discovery and development of a drug takes place under one roof.

This should work with the Association of small and large companies, mainly in the later stages of development.

And scientific advances, Adds the expert, they are also allowing for the possibility of new pharmaceutical discoveries.

“Science is moving away from the old model of pharmaceutical production: toward personalized medicine”.

“With this you can identify the patient that will benefit from compound determined by subjecting it to a genetic test”.

“It will thus benefit a small number of patients but will benefit extremely well” Adds.

The collaboration, experts say, It is the key to future success in the pharmaceutical field.

In particular the cooperation in the early stages of the development of a drug.

As Professor Vallance, the largest competition will be in the final stages of a drug.

“There will be a fierce competition to be the first to get the best medicine, to make sure that we are doing a proper trial and that we can prove that we we get the best medication” expresses the Professor Vallance. [en línea] London (UK): 31 de mayo de 2012 [REF. 27 in May of 2012] Available on Internet: